Mereo BioPharma Group PLC (MREO)
3.525
-0.30
(-7.72%)
USD |
NASDAQ |
Nov 15, 16:00
3.525
0.00 (0.00%)
After-Hours: 18:47
Mereo BioPharma Group Free Cash Flow (Quarterly): -7.903M for June 30, 2024
Free Cash Flow (Quarterly) Chart
Historical Free Cash Flow (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | -7.903M |
| March 31, 2024 | -8.691M |
| Date | Value |
|---|---|
| June 30, 2023 | -7.754M |
| March 31, 2023 | -9.667M |
Free Cash Flow Definition
Free cash flow measures the amount of cash left over from a time period after all operational and working capital payments are made. Free cash flow is an important metric because it allows you to view the amount actual cash is available to the company. Free cash flow is also commonly used in valuation calculations like the discounted cash flow valuation model.
Free Cash Flow (Quarterly) Range, Past 5 Years
-9.667M
Minimum
Mar 2023
-7.754M
Maximum
Jun 2023
-8.504M
Average
-8.297M
Median
Free Cash Flow (Quarterly) Benchmarks
| NuCana PLC | -1.569M |
| TC BioPharm (Holdings) PLC | -3.062M |
| Adaptimmune Therapeutics PLC | 46.64M |
| Biodexa Pharmaceuticals PLC | -- |
| Autolus Therapeutics PLC | -51.92M |